New computer model could lead to safer stentsDecember 03, 2009CAMBRIDGE, Mass. - MIT scientists including Elazer R. Edelman, the Thomas D. and Virginia W. Cabot Professor of Health Science and Technology (HST), and HST postdoctoral associate Vijaya B. Kolachalama, developed computer models to predict physiologically realistic drug delivery patterns from stents in branched arterial vessels. They simulated several arterial settings to show that drug distribution in these situations is determined by a complex calculation of the stent's position relative to arterial branches and constant blood flow changes caused by the branching. "We now demonstrate for the first time that spatial variation in drug distribution can be significant when appreciated from a three-dimensional perspective and this viewpoint can only be gained with the use of these model systems," said Edelman. Drug-eluting stents are now widely used all over the world to treat obstructive arterial disease, yet some patients with the stents have suffered life-threatening side effects: an increase risk of blood clotting and heart attacks. Several important questions remain unanswered - in particular, the mechanisms that govern drug delivery to specific lesion sites are poorly defined and pose challenges for stent designers, physicians, and regulatory agencies that must evaluate stents' safety and efficacy. Predicting drug distribution is complicated by the branching of arteries into two or more vessels, which establishes alterations in flow, wall shear stress and geometries. All of those can be modeled and defined mathematically, however, the variations cannot be captured across the full spectrum of perturbations and combinations in animal systems or in the lab, let alone the human. Computational models are therefore required. "By observing the arterial drug distribution patterns for various settings, we understood that drug released from the stent does not reach uniformly to all regions of the vessel and this non-uniformity depends on where the stent is placed in the artery as well as the blood flow that is entering the vessel," says Edelman. "Appreciating this phenomenon for more complex cases like branched vessels is non-intuitive, but now we have a computer model that gave us the much needed insight." "Modeling stent-based drug delivery in branched vessels is critically important because these are frequent sites of arterial disease and yet there are no dedicated devices that are FDA-approved or efficient strategies using multiple stents to specifically treat these locations," says Kolachalama. "Our computer model shows that for some arterial settings, a single stent in the main-branch of the fork can provide drug to the side-branch. This observation could be important to consider, especially when one has to place stents in both branches." How they did it: The computer model was generated by combining principles of digital image processing and parametric computer-aided geometry design with computational fluid dynamics and mass transport. A video link showing how these geometry models are created can be found on the journal website. The authors believe this modeling technique can be extended to simulate several settings with various stent designs as well as complex arterial geometries with and without disease, altered flow environments and other boundary conditions. Massachusetts Institute of Technology |
|||||||||||||||||||||
| Related Stents Current Events and Stents News Articles Device advances interventional radiology treatment to clear blocked carotid arteries, prevent stroke An important interventional radiology advancement-the use of a new cerebral protection device in combination with FDA-approved carotid stents in high-surgical-risk patients-provides a minimally invasive, safe and effective way to prevent stroke from occurring during treatment to clear blocked carotid arteries. New nanoparticles target cardiovascular disease Researchers at MIT and Harvard Medical School have built targeted nanoparticles that can cling to artery walls and slowly release medicine, an advance that potentially provides an alternative to drug-releasing stents in some patients with cardiovascular disease. Findings suggest cardiovascular devices often approved by FDA without high-quality studies Pre-market approval by the FDA of cardiovascular devices is often based on studies that lack adequate strength or may have been prone to bias, according to a study in the December 23/30 issue of JAMA. New computer model could lead to safer stents After suffering heart attacks, patients often receive stents designed to hold their arteries open. Some of these stents release drugs that are meant to halt tissue growth in arteries, but can have life-threatening side effects such as increasing the likelihood of blood clots and heart attacks. Engineers, doctors at UCLA develop novel material that could help fight arterial disease A fortuitous discovery that grew out of a collaboration between UCLA engineers and physicians could potentially offer hope to the nearly 10 million Americans who suffer from peripheral arterial disease. Your Own Stem Cells Can Treat Heart Disease The largest national stem cell study for heart disease showed the first evidence that transplanting a potent form of adult stem cells into the heart muscle of subjects with severe angina results in less pain and an improved ability to walk. The transplant subjects also experienced fewer deaths than those who didn't receive stem cells. Vitamin B niacin offers no extra benefit to statin therapy in seniors already diagnosed with CAD The routine prescription of extended-release niacin, a B vitamin (1,500 milligrams daily), in combination with traditional cholesterol-lowering therapy offers no extra benefit in correcting arterial narrowing and diminishing plaque buildup in seniors who already have coronary artery disease, a new vascular imaging study from Johns Hopkins experts shows. Higher carotid arterial stenting rates associated with poorer clinical outcomes Among eligible Medicare beneficiaries, increased use of carotid arterial stenting (CAS) procedures to treat carotid stenosis-the narrowing of the carotid artery-is associated with higher rates of mortality and adverse clinical outcomes, including heart attack and stroke, according to researchers from the University of Pennsylvania School of Medicine. Drug-eluting stents better than bare-metal stents for heart attack patients Late-breaking data from the landmark HORIZONS-AMI clinical trial, presented at the 21st annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, demonstrated that after two years, in heart attack patients, the use of a drug-eluting stent (paclitaxel) was safer and more effective than a bare-metal stent; and that the administration of the anticoagulant medication bivalirudin enhanced safety and efficacy compared to the use of heparin + GPIIb/IIIa inhibitors. SPIRIT IV trial shows everolimus stent sets new standard for event-free survival Late-breaking data from SPIRIT IV, a large-scale multi-center study of nearly 4,000 patients in the U.S., shows that an everolimus-eluting stent demonstrated enhanced safety and efficacy in the treatment of de novo native coronary artery lesions when compared to a paclitaxel-eluting stent, and showed that "low late loss" may be achieved with drug-eluting stents without sacrificing safety. More Stents Current Events and Stents News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||